Working together

The Efficient and Innovative design of I-SPY 2 offers all of our partners — clinical researchers, patient advocates, pharmaceutical and diagnostics companies, and non-profit charities — the opportunity to participate in and contribute to the acceleration of drug development to treat breast cancer patients in the neoadjuvant setting. 

A leap in collaboration begins here

The I-SPY Trials are always looking to discuss potential partnerships with companies interested in evaluating promising new agents or analytical methods.  To learn more about partnerships with I-SPY, please contact Paul Henderson at

OneSource AI

Leverage our database for deeper insights

OneSource AI provides access to secure analytic workspaces and data for partners to explore and develop models and AI algorithms leveraging data from the I-SPY family of trials.  Datasets include clinical, imaging, biomarker and sequencing data.

Learn more about OneSource.

For Investigators

Proposal Submissions

I-SPY 2 accepts proposals from investigators interested in accessing I-SPY data or clinical specimens for original research. The following information describes the general requirements, application and review processes. Interested applicants should familiarize themselves with this information prior to submission.

I-SPY 2 Leadership

Meet the leading minds leading our innovative cancer trials.

A leap in research happens with world-class partners.

Together with our incredible partners in the pharma and healthcare world,
we’re making bigger leaps than ever before to advance personalized medicine for all.

I-SPY Articles & Publications

Find the latest leaps happening near you.

40-site U.S. trial enrolling more than 300 patients could significantly change the way DCIS is treated and reduce possibly unnecessary surgery
Quantum Leap Healthcare Collaborative™ today announced that Arvinas’ vepdegestrant (ARV-471), a novel PROTAC® estrogen receptor (ER) protein degrader being co-developed with Pfizer Inc. will be evaluated in the ongoing I-SPY TRIAL endocrine program sponsored by Quantum Leap.
Exai Bio today announced a collaboration agreement with Quantum Leap Healthcare Collaborative™ (QLHC) to expand the use of Exai’s novel, RNA-based liquid biopsy platform to monitor patients’ treatment response and disease burden in the I-SPY 2 TRIAL. I-SPY2 is the largest and longest-running 'platform' trial that provides a regulatory framework to study multiple novel therapeutic treatment arms for women with newly diagnosed, locally advanced breast cancer. 
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, and Quantum Leap Healthcare Collaborative™ today announce that Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM),(Z)-endoxifen, will be evaluated in a new study arm of the ongoing I-SPY 2clinical trial.
Contact Us
Investigators Portal
QLHC in the News
Working at QL
Contact Us